Zagam

Zagam®

Sparfloxacin, see there.
References in periodicals archive ?
Prokocimer, formerly a Vice President for Johnson & Johnson Pharmaceuticals and, before that Vice President of Anti-infectives Clinical Research with Aventis Pharmaceuticals, has been developing anti-infective drugs for the past 20 years and has been involved with the filing of five New Drug Applications (NDAs) including the antibiotics Doripenem, Synercid, Zagam (sparfloxacin) and Biaxin.
A,B) In addition, patients who had failed previous therapy with other antibiotics for acute bacterial exacerbations of chronic bronchitis had a bacterial eradication rate of 88 percent when treated with ZAGAM, compared with 79 percent in the Biaxin group.
The efficacy and safety of ZAGAM (400-mg loading dose followed by 200 mg once daily for 10 days) was compared to Biaxin (500 mg twice daily for 10 days) in a randomized, double-blind, multicenter study in 298 adults (145 ZAGAM, 153 Biaxin) with acute bacterial exacerbations of chronic bronchitis who had failed previous therapy.
The number of Americans who develop a respiratory illness this winter may top last year's total of approximately 74 million, according to Z-RAN, the ZAGAM Respiratory Alert Network.
Unlike earlier generation quinolone antibiotics, ZAGAM is active against community-acquired lower profile and once-daily dosing make it an attractive option.
ZAGAM recently received clearance for marketing from the U.
Cawthorn, Chairman and Chief Executive Officer, "and resulted from improved performance of our key strategic products including Azmacort, Lovenox, Granocyte, Zagam as well as our plasma protein therapies.
In France, the new quinolone antibiotic Zagam, launched in September, quickly gained leadership in its class.
However, the new quinolone antibiotic Zagam was launched there
A registration dossier for the quinolone antibiotic Zagam was approved in France and submitted in several other European countries in 1993 and will be submitted throughout the rest of Europe in the coming months.
In community acquired pneumonia, sinusitis and chronic bronchitis, Zagam has demonstrated at least as high efficacy as the best reference drugs (including macrolides and beta lactams).
A registration dossier for the quinolone antibiotic Zagam was subhas signed a licensing agreement to further extend its rights to market this product in an additional 70 countries in South America, the Middle East and southeast Asia.